01:28 , Apr 21, 2018 |  BioCentury  |  Product Development

Redrawing the lines

Word that Merck & Co. Inc.’s Keytruda pembrolizumab had “won” the first-line lung cancer showdown with Bristol-Myers Squibb Co. at AACR spread quickly on Monday, but there was little discussion among investors and in the...
08:00 , Jan 30, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer; colon cancer Programmed cell death 1 ligand 1 (CD274 molecule; PD-L1;...
08:00 , Jan 7, 2013 |  BioCentury  |  Finance

Buyside View XXI: Sunny side up

Stephen Hansen Senior Writer  A strong crop of early PDUFA dates and a sense that FDA is more navigable have given money managers in the U.S. and Europe a positive outlook for 2013, which they hope...
08:00 , Nov 5, 2012 |  BioCentury  |  Emerging Company Profile

ImmuNext: New VISTAs

ImmuNext Inc. has developed an antagonist of VISTA, a ligand that negatively regulates T cells similar to better known members of the B7 family of proteins. But targeting VISTA could be safer than targeting other...
07:00 , Jun 18, 2012 |  BioCentury  |  Product Development

Immune springboard

A spate of Phase III data events over the next two years will give a readout on how correctly the lessons learned five years ago about cancer immunotherapies targeting T cell responses have been put...
07:00 , Jun 11, 2012 |  BC Week In Review  |  Clinical News

Anti-PD-L1: Phase I data

Data from 160 evaluable patients with advanced solid tumors in the open-label, U.S. Phase I MDX1105-01 trial showed that IV BMS-936559 produced an objective response in 9 (17%) melanoma patients (n=52), 5 (10%) non-small cell...
00:47 , Jun 5, 2012 |  BC Extra  |  Clinical News

Bristol-Myers reports data for anti-PD-L1 mAb

Bristol-Myers Squibb Co. (NYSE:BMY) reported data from 160 evaluable patients with advanced solid tumors in the Phase I MDX1105-01 trial of BMS-936559, a human mAb against programmed cell death 1 ligand 1 ( CD274 molecule;...
07:00 , Jul 27, 2009 |  BioCentury  |  Strategy

Medarex pipeline

Medarex pipeline Therapeutics Product [Partner] Target Status [Lead indication] Ipilimumab (MDX-010) [Bristol-Myers Squibb Co. (NYSE:BMY)] CTLA-4 (CD152) receptor Ph III [melanoma] MDX-1100 Chemokine CXC motif ligand 10...
08:00 , Dec 18, 2008 |  BC Innovations  |  Targets & Mechanisms

Second wind for T cells

In the battle against HIV, HBV and HCV, all of which establish persistent infections that eventually wear down the antiviral cytotoxic T cell response, the odds for the immune system are poor. Three studies now...
07:00 , Aug 11, 2008 |  BC Week In Review  |  Clinical News

MDX-1105: Phase I start

Medarex will begin an open-label, dose-escalation Phase I trial in up to 46 patients with advanced or recurrent solid tumors. Medarex Inc. (NASDAQ:MEDX), Princeton, N.J.   Product: MDX-1105   Business: Cancer   Molecular target: NA   Description: Human...